Drugs / RO6864018
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02015715 | Dec 2013 → Nov 2014 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02391805 | May 2015 → Oct 2017 | chronic hepatitis B virus infection | Hoffmann-La Roche | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RO6864018 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02015715 ↗ |
| Route | Oral | “A single oral ascending dose of RO6864018 capsules on Day 1.” NCT02015715 ↗ |